Eisai Co., Ltd. produces prescription drugs and medical equipment and sells mainly to sales agents and subsidiaries.  Through its subsidiary, Sanko Junyaku, the Company produces and sells diagnostic drugs.  Eisai also markets its products through related companies in the US, Europe, and Asia.  The Company also manufactures and sells foods, livestock feeds, chemical, and agrochemicals.

Eisai Receives Positive Opinion From The Chmp In The European Union For Lecanemab In Early Alzheimer’S Disease

Consolidated Financial Report [Ifrs] For The Six-Month Period Ended September 30, 2024

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Eisai Co Ltd (4523 JP)

Eisai Receives Positive Opinion From The Chmp In The European Union For Lecanemab In Early Alzheimer’S Disease

Consolidated Financial Report [Ifrs] For The Six-Month Period Ended September 30, 2024

Financial Results For The Six-Month Period Ended September 30,2024 Reference Data

Revenue Of Leqembi (Preliminary Basis)

Eisai Announces Status And Completion Of Acquisition Of Own Shares

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)